Trials / Completed
CompletedNCT02189109
The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma
A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- NuvOx LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy. NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NVX-108 | 0.2% emulsion administered i.v. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2017-08-31
- Completion
- 2018-04-01
- First posted
- 2014-07-14
- Last updated
- 2019-02-28
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT02189109. Inclusion in this directory is not an endorsement.